Study Summary
This trial is examining how well different exercises work to improve muscle function in people with chronic back pain from a herniated disc.
Eligible Conditions
- Disc Degeneration
- Lower Back Pain
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 59 Secondary · Reporting Duration: 6 months
6 Months
Change in Oswestry Disability Index (ODI)
Hour 6
ADIPOQ Protein abundance (ug/mg)
ADIPOQ gene expression (delta CT/delta CT)
ANKRD2 gene expression (delta CT/delta CT)
ANKRD2 protein abundance (ug/mg)
CASP1 Protein abundance (ug/mg)
CASP1 gene expression (delta CT/delta CT)
CASP3 Protein abundance (ug/mg)
CASP3 gene expression (delta CT/delta CT)
CEBPA Protein abundance (ug/mg)
CEBPA gene expression (delta CT/delta CT)
COL1A1 Protein abundance (ug/mg)
COL1A1 gene expression (delta CT/delta CT)
COL3A1 Protein abundance (ug/mg)
COL3A1 gene expression (delta CT/delta CT)
COL9A1 Protein abundance (ug/mg)
COL9A1 gene expression (delta CT/delta CT)
CTGF Protein abundance (ug/mg)
CTGF gene expression (delta CT/delta CT)
FABP4 Protein abundance (ug/mg)
FABP4 gene expression (delta CT/delta CT)
IL10 Protein abundance (ug/mg)
IL10 gene expression (delta CT/delta CT)
IL1B Protein abundance (ug/mg)
IL1B gene expression (delta CT/delta CT)
IL6 Protein abundance (ug/mg)
IL6 gene expression (delta CT/delta CT)
LEP Protein abundance (ug/mg)
LEP gene expression (delta CT/delta CT)
LOX Protein abundance (ug/mg)
LOX gene expression (delta CT/delta CT)
GRB2 Adaptor Protein
MMP1 Protein abundance (ug/mg)
MMP1 gene expression (delta CT/delta CT)
MMP3 Protein abundance (ug/mg)
MMP3 gene expression (delta CT/delta CT)
MMP9 Protein abundance (ug/mg)
MMP9 gene expression (delta CT/delta CT)
MTOR gene expression (delta CT/delta CT)
MTOR protein abundance (ug/mg)
MYHC3 gene expression (delta CT/delta CT)
MYOG gene expression (delta CT/delta CT)
MYOG protein abundance (ug/mg)
PAX7 gene expression (delta CT/delta CT)
PAX7 gene expression (ug/mg)
PPARD Protein abundance (ug/mg)
PPARD gene expression (delta CT/delta CT)
PPARG Protein abundance (ug/mg)
PPARG gene expression (delta CT/delta CT)
TGFB1 Protein abundance (ug/mg)
TGFB1 gene expression (delta CT/delta CT)
TNFa Protein abundance (ug/mg)
TNFa gene expression (delta CT/delta CT)
6 months
Change in Fear Avoidance Beliefs Questionnaire (FABQ)
Change in Multifidus Muscle Fatty Infiltration
Change in Pain (VAS)
Change in Pain Catastrophizing Scale (PCS)
Change in Strength
After exercise (within 5 minutes)
Change in Activated Muscle Volume (%)
baseline
Structure of multifidus muscle
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Non-exercise
1 of 2
Exercise
1 of 2
Active Control
Experimental Treatment
40 Total Participants · 2 Treatment Groups
Primary Treatment: Exercise · No Placebo Group · N/A
Exercise
Other
Experimental Group · 1 Intervention: Exercise · Intervention Types: OtherNon-exerciseNoIntervention Group · 1 Intervention: Non-exercise · Intervention Types:
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months
Who is running the clinical trial?
University of California, San DiegoLead Sponsor
1,027 Previous Clinical Trials
1,795,981 Total Patients Enrolled
Balgrist University HospitalOTHER
83 Previous Clinical Trials
511,630 Total Patients Enrolled
Spine Institute of San Diego (Spine Zone)UNKNOWN
Eligibility Criteria
Age 21 - 85 · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments